{"prompt": "['NOTE: To classify a response as PR, the participant must have at least a PR in', 'either the cutaneous or noncutaneous sites of disease, and no evidence of', 'progression as defined in the above criteria.', 'NOTE: Participants with residual tumor-associated edema or effusion who', 'otherwise meet the criteria for CR will be classified as having a PR.', '9.1.3 Stable disease (SD) is defined as any response not meeting the criteria for CR, PR,', 'or progressive disease.', '9.1.4 Progressive disease (PD) is defined as follows:', 'For participants with <50 cutaneous lesions', 'PD is defined as any one or more of the following:', '> 25% increase in the area of the cutaneous marker lesions compared to entry', 'or best response;', '> 25% increase in the total lesion count, or a minimum of five new lesions,', 'whichever is greater, compared with entry or best response;', '> 25% increase in the number of raised lesions, or a minimum of five new raised', 'lesions, whichever is greater, compared with entry or best response.', 'NOTE: There are body sites where disease is particularly difficult to evaluate, and', 'a few new lesions may be counted in spite of the fact that a participant is not actually', 'progressing. For example, lesions of the foot, particularly those that are flat, are', 'difficult to evaluate because their intensity may vary based on how much edema is', 'present, how much the person walked the day before, how long his/her feet have', 'been in a dependent position prior to the physical exam.', 'For participants with >50 cutaneous lesions', 'PD is defined as any one or more of the following:', '> 25% increase in the area of the cutaneous marker lesions compared to entry', 'or best response;', '>', '25% increase in the total number of lesions in the prospectively defined', 'anatomic sites containing representative lesions;', 'a total of five new lesions in anatomic sites that were previously documented', 'as having no evidence of cutaneous disease,', '> 25% increase in the number of raised lesions in the prospectively defined', 'anatomic sites containing representative lesions (minimum of five raised', 'lesions if there are very few raised lesions, for example < 8) whichever is', 'greater. Photographic documentation of \"gross\" or significant progression,', 'particularly in areas that were not being followed, will be of particular value.', '9.1.5 Noncutaneous progression (PD): Noncutaneous PD includes new oral or visceral', 'sites of involvement or progression of oral or visceral disease or the development', 'of new or increasing tumor-associated edema or effusion that interferes with the', \"participant's normal activities lasting for at least two consecutive evaluations.\", 'AMC-S007 (Version 2.0) 20MAR2018', '37', 'NCI Version Date 20MAR2018']['Progressive oral or visceral disease, for measurable and evaluable disease, should', 'be analogous to cutaneous KS response criteria.', 'Progressive edema is defined as the following:', 'An increase in non-pitting/woody edema in an upper or lower extremity', 'associated with an increase in limb circumference of at least 3 cm from entry or', 'best response, sustained for at least two consecutive evaluations, and measured', 'at a fixed point on the extremity with respect to a bony landmark (e.g., 10 cm', 'below the lower border of the patella); AND/OR', 'New appearance of non-pitting/woody edema in an extremity where none was', 'previously present, sustained for at least two consecutive evaluations; AND/OR', 'New or worsening edema in a non-extremity site (e.g., periorbital, genital) that', 'interferes with function and is sustained for at least two consecutive', 'evaluations.', '9.1.6 Recurrent disease', 'Recurrent disease is defined as the appearance of tumor following documentation', 'of a complete remission.', '9.1.7 Time to response', 'Time to response is defined as time from the first dose of chemotherapy until', 'documentation of first response.', '9.1.8 Time to progression', 'Time to progression is defined as time from initiation of chemotherapy to', 'documentation of first progression.', '9.1.9 Response duration', 'Response duration is defined as the time from first documentation of response to', 'documentation of first progression.', 'AMC-S007 (Version 2.0) 20MAR2018', '38', 'NCI Version Date 20MAR2018']\n\n###\n\n", "completion": "END"}